Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

NCT07284667 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT07284667
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07284667 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of ACP-211 Monotherapy in Adults With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
November 14, 2025
Completion date
September 30, 2027
Enrollment
153 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, treatment-resistant, major depressive disorder (mdd)